Letter: Hepatitis B and MAFLD - a consilience of risk factors for hepatocellular carcinoma
- PMID: 34379831
- DOI: 10.1111/apt.16532
Letter: Hepatitis B and MAFLD - a consilience of risk factors for hepatocellular carcinoma
Comment on
-
Modelling NAFLD disease burden in four Asian regions-2019-2030.Aliment Pharmacol Ther. 2020 Apr;51(8):801-811. doi: 10.1111/apt.15673. Epub 2020 Mar 4. Aliment Pharmacol Ther. 2020. PMID: 32133676 Free PMC article.
References
REFERENCES
-
- Estes C, Chan HLY, Chien RN, et al. Modelling NAFLD disease burden in four Asian regions-2019-2030. Aliment Pharmacol Ther. 2020;51:801-811.
-
- Yip TC, Wong VW. Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on antiviral therapy. Aliment Pharmacol Ther. 2021;54:722-723.
-
- Khalili M, Kleiner DE, King WC, et al. Hepatic steatosis and steatohepatitis in a large North American cohort of adults with chronic hepatitis B. Am J Gastroenterol. 2021. http://doi.org/10.14309/ajg.0000000000001257
-
- Peleg N, Issachar A, Sneh Arbib O, et al. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response. J Viral Hepat. 2019;26:1257-1265.
-
- Chan TT, Chan WK, Wong GL, et al. Positive hepatitis B core antibody is associated with cirrhosis and hepatocellular carcinoma in nonalcoholic fatty liver disease. Am J Gastroenterol. 2020;115:867-875.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical